NASDAQ:ICAD

iCAD Competitors

$17.88
-0.67 (-3.61 %)
(As of 04/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$17.60
Now: $17.88
$18.58
50-Day Range
$16.55
MA: $18.71
$21.22
52-Week Range
$8.25
Now: $17.88
$21.44
Volume159,818 shs
Average Volume212,563 shs
Market Capitalization$445.53 million
P/E RatioN/A
Dividend YieldN/A
Beta1.3

Competitors

iCAD (NASDAQ:ICAD) Vs. LMNX, GNMK, INO, SILK, ATEC, and LUNG

Should you be buying ICAD stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to iCAD, including Luminex (LMNX), GenMark Diagnostics (GNMK), Inovio Pharmaceuticals (INO), Silk Road Medical (SILK), Alphatec (ATEC), and Pulmonx (LUNG).

Luminex (NASDAQ:LMNX) and iCAD (NASDAQ:ICAD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings.

Institutional and Insider Ownership

88.1% of Luminex shares are held by institutional investors. Comparatively, 44.8% of iCAD shares are held by institutional investors. 9.4% of Luminex shares are held by company insiders. Comparatively, 12.4% of iCAD shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Luminex and iCAD's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Luminex4.60%3.75%2.73%
iCAD-67.61%-55.84%-22.93%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Luminex and iCAD, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Luminex01102.50
iCAD00603.00

Luminex presently has a consensus price target of $38.00, indicating a potential upside of 2.62%. iCAD has a consensus price target of $22.8333, indicating a potential upside of 27.70%. Given iCAD's stronger consensus rating and higher probable upside, analysts plainly believe iCAD is more favorable than Luminex.

Earnings & Valuation

This table compares Luminex and iCAD's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Luminex$334.64 million5.23$-3,840,000.00($0.21)-176.33
iCAD$31.34 million14.22$-13,550,000.00($0.37)-48.32

Luminex has higher revenue and earnings than iCAD. Luminex is trading at a lower price-to-earnings ratio than iCAD, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Luminex has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, iCAD has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500.

Summary

Luminex beats iCAD on 8 of the 14 factors compared between the two stocks.

iCAD (NASDAQ:ICAD) and GenMark Diagnostics (NASDAQ:GNMK) are both small-cap computer and technology companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

Analyst Ratings

This is a breakdown of current ratings and price targets for iCAD and GenMark Diagnostics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
iCAD00603.00
GenMark Diagnostics05002.00

iCAD presently has a consensus price target of $22.8333, suggesting a potential upside of 27.70%. GenMark Diagnostics has a consensus price target of $22.0125, suggesting a potential downside of 7.86%. Given iCAD's stronger consensus rating and higher possible upside, analysts clearly believe iCAD is more favorable than GenMark Diagnostics.

Risk & Volatility

iCAD has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500. Comparatively, GenMark Diagnostics has a beta of 3.02, suggesting that its stock price is 202% more volatile than the S&P 500.

Institutional & Insider Ownership

44.8% of iCAD shares are owned by institutional investors. Comparatively, 96.9% of GenMark Diagnostics shares are owned by institutional investors. 12.4% of iCAD shares are owned by insiders. Comparatively, 3.3% of GenMark Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares iCAD and GenMark Diagnostics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
iCAD-67.61%-55.84%-22.93%
GenMark Diagnostics-16.95%-39.36%-13.02%

Earnings and Valuation

This table compares iCAD and GenMark Diagnostics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iCAD$31.34 million14.22$-13,550,000.00($0.37)-48.32
GenMark Diagnostics$88.02 million19.84$-47,350,000.00($0.82)-29.13

iCAD has higher earnings, but lower revenue than GenMark Diagnostics. iCAD is trading at a lower price-to-earnings ratio than GenMark Diagnostics, indicating that it is currently the more affordable of the two stocks.

Inovio Pharmaceuticals (NASDAQ:INO) and iCAD (NASDAQ:ICAD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Inovio Pharmaceuticals and iCAD, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inovio Pharmaceuticals14302.25
iCAD00603.00

Inovio Pharmaceuticals presently has a consensus price target of $17.00, indicating a potential upside of 106.31%. iCAD has a consensus price target of $22.8333, indicating a potential upside of 27.70%. Given Inovio Pharmaceuticals' higher probable upside, equities analysts plainly believe Inovio Pharmaceuticals is more favorable than iCAD.

Profitability

This table compares Inovio Pharmaceuticals and iCAD's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Inovio Pharmaceuticals-8,518.10%-78.17%-40.33%
iCAD-67.61%-55.84%-22.93%

Volatility & Risk

Inovio Pharmaceuticals has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, iCAD has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500.

Earnings and Valuation

This table compares Inovio Pharmaceuticals and iCAD's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inovio Pharmaceuticals$4.11 million417.63$-119,360,000.00($1.16)-7.10
iCAD$31.34 million14.22$-13,550,000.00($0.37)-48.32

iCAD has higher revenue and earnings than Inovio Pharmaceuticals. iCAD is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

36.0% of Inovio Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.8% of iCAD shares are owned by institutional investors. 4.0% of Inovio Pharmaceuticals shares are owned by company insiders. Comparatively, 12.4% of iCAD shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

iCAD beats Inovio Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

Silk Road Medical (NASDAQ:SILK) and iCAD (NASDAQ:ICAD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, analyst recommendations, risk, institutional ownership, profitability and earnings.

Profitability

This table compares Silk Road Medical and iCAD's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Silk Road Medical-53.66%-40.79%-24.56%
iCAD-67.61%-55.84%-22.93%

Volatility & Risk

Silk Road Medical has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500. Comparatively, iCAD has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Silk Road Medical and iCAD, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Silk Road Medical02202.50
iCAD00603.00

Silk Road Medical currently has a consensus target price of $61.75, indicating a potential upside of 24.67%. iCAD has a consensus target price of $22.8333, indicating a potential upside of 27.70%. Given iCAD's stronger consensus rating and higher possible upside, analysts clearly believe iCAD is more favorable than Silk Road Medical.

Valuation and Earnings

This table compares Silk Road Medical and iCAD's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silk Road Medical$63.35 million26.87$-52,420,000.00($1.36)-36.42
iCAD$31.34 million14.22$-13,550,000.00($0.37)-48.32

iCAD has lower revenue, but higher earnings than Silk Road Medical. iCAD is trading at a lower price-to-earnings ratio than Silk Road Medical, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

44.8% of iCAD shares are held by institutional investors. 7.8% of Silk Road Medical shares are held by company insiders. Comparatively, 12.4% of iCAD shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

iCAD beats Silk Road Medical on 9 of the 14 factors compared between the two stocks.

Alphatec (NASDAQ:ATEC) and iCAD (NASDAQ:ICAD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, institutional ownership, risk, dividends and earnings.

Analyst Ratings

This is a summary of current recommendations for Alphatec and iCAD, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alphatec00703.00
iCAD00603.00

Alphatec currently has a consensus target price of $15.4286, suggesting a potential downside of 9.77%. iCAD has a consensus target price of $22.8333, suggesting a potential upside of 27.70%. Given iCAD's higher probable upside, analysts clearly believe iCAD is more favorable than Alphatec.

Valuation and Earnings

This table compares Alphatec and iCAD's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alphatec$113.43 million14.34$-57,000,000.00($1.09)-15.69
iCAD$31.34 million14.22$-13,550,000.00($0.37)-48.32

iCAD has lower revenue, but higher earnings than Alphatec. iCAD is trading at a lower price-to-earnings ratio than Alphatec, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Alphatec has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500. Comparatively, iCAD has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500.

Insider & Institutional Ownership

31.8% of Alphatec shares are owned by institutional investors. Comparatively, 44.8% of iCAD shares are owned by institutional investors. 28.2% of Alphatec shares are owned by insiders. Comparatively, 12.4% of iCAD shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Alphatec and iCAD's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alphatec-51.95%-266.45%-40.80%
iCAD-67.61%-55.84%-22.93%

Summary

Alphatec beats iCAD on 7 of the 13 factors compared between the two stocks.

Pulmonx (NASDAQ:LUNG) and iCAD (NASDAQ:ICAD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

Earnings & Valuation

This table compares Pulmonx and iCAD's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pulmonx$32.60 million47.15$-20,700,000.00N/AN/A
iCAD$31.34 million14.22$-13,550,000.00($0.37)-48.32

iCAD has lower revenue, but higher earnings than Pulmonx.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Pulmonx and iCAD, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pulmonx03502.63
iCAD00603.00

Pulmonx currently has a consensus price target of $58.00, suggesting a potential upside of 34.66%. iCAD has a consensus price target of $22.8333, suggesting a potential upside of 27.70%. Given Pulmonx's higher possible upside, equities analysts plainly believe Pulmonx is more favorable than iCAD.

Insider and Institutional Ownership

44.8% of iCAD shares are held by institutional investors. 12.4% of iCAD shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Pulmonx and iCAD's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PulmonxN/AN/AN/A
iCAD-67.61%-55.84%-22.93%

Summary

Pulmonx beats iCAD on 6 of the 11 factors compared between the two stocks.


iCAD Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Luminex logo
LMNX
Luminex
1.5$37.03-11.0%$1.75 billion$334.64 million94.95Analyst Upgrade
Unusual Options Activity
News Coverage
Gap Down
GenMark Diagnostics logo
GNMK
GenMark Diagnostics
1.5$23.89-0.4%$1.75 billion$88.02 million-58.27
Inovio Pharmaceuticals logo
INO
Inovio Pharmaceuticals
1.4$8.24-5.8%$1.72 billion$4.11 million-6.06
Silk Road Medical logo
SILK
Silk Road Medical
1.1$49.53-1.2%$1.70 billion$63.35 million-40.60
Alphatec logo
ATEC
Alphatec
0.8$17.10-2.9%$1.63 billion$113.43 million-15.55Analyst Report
Insider Selling
Pulmonx logo
LUNG
Pulmonx
1.4$43.07-1.0%$1.54 billion$32.60 million0.00High Trading Volume
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$36.74-1.7%$1.48 billion$236.54 million-55.67
MiMedx Group logo
MDXG
MiMedx Group
1.7$12.41-2.5%$1.38 billion$299.26 million-13.20
Atrion logo
ATRI
Atrion
1.1$645.10-0.2%$1.18 billion$155.07 million36.34News Coverage
SI-BONE logo
SIBN
SI-BONE
1.2$33.66-0.3%$1.10 billion$67.30 million-21.04
Tactile Systems Technology logo
TCMD
Tactile Systems Technology
1.2$53.82-0.3%$1.06 billion$189.49 million-119.60
LeMaitre Vascular logo
LMAT
LeMaitre Vascular
1.9$49.90-3.1%$1.02 billion$117.23 million53.66
Cerus logo
CERS
Cerus
1.7$6.07-1.0%$1.02 billion$74.65 million-15.56Analyst Revision
Gap Up
OrthoPediatrics logo
KIDS
OrthoPediatrics
1.5$49.35-0.4%$970.12 million$72.55 million-34.27
AngioDynamics logo
ANGO
AngioDynamics
1.4$23.34-1.8%$890.12 million$264.16 million-5.22
CryoLife logo
CRY
CryoLife
2.0$22.48-0.6%$879.42 million$276.22 million-59.16News Coverage
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$42.05-2.0%$820.48 million$459.95 million35.04
Surmodics logo
SRDX
Surmodics
1.3$57.03-0.2%$784.51 million$94.86 million712.88News Coverage
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$10.05-3.7%$723.06 million$154.60 million-43.70
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.07-0.7%$684.42 million$123.86 million67.84
Intersect ENT logo
XENT
Intersect ENT
1.4$20.04-2.2%$661.64 million$109.14 million-10.49
SeaSpine logo
SPNE
SeaSpine
1.3$21.39-2.6%$597.49 million$159.08 million-12.81Analyst Revision
Vapotherm logo
VAPO
Vapotherm
1.5$22.89-1.6%$590.72 million$48.10 million-10.90
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$40.40-1.5%$578.93 million$114.51 million-85.96
Pulse Biosciences logo
PLSE
Pulse Biosciences
1.5$21.64-0.8%$564.52 millionN/A-9.53
Accuray logo
ARAY
Accuray
2.3$5.18-0.6%$481.21 million$382.93 million37.00
PAVmed logo
PAVM
PAVmed
1.2$5.78-3.8%$476.63 millionN/A-7.61
AVITA Medical logo
RCEL
AVITA Medical
1.5$20.59-2.3%$445.34 million$14.26 million-9.95Analyst Downgrade
News Coverage
ClearPoint Neuro logo
CLPT
ClearPoint Neuro
1.4$21.47-3.0%$443.85 million$11.22 million-48.80
Profound Medical logo
PROF
Profound Medical
1.6$19.97-2.7%$405.19 million$4.17 million-17.07
Cytosorbents logo
CTSO
Cytosorbents
1.7$8.99-1.0%$388.94 million$24.95 million-27.24
UFP Technologies logo
UFPT
UFP Technologies
1.3$49.94-0.4%$375.55 million$198.38 million24.97
Soliton logo
SOLY
Soliton
1.1$16.96-7.6%$359.55 millionN/A-22.61News Coverage
Acutus Medical logo
AFIB
Acutus Medical
1.3$12.47-5.9%$350.35 million$2.84 million0.00
Apyx Medical logo
APYX
Apyx Medical
1.0$9.38-1.3%$321.90 million$28.15 million-19.96
Neuronetics logo
STIM
Neuronetics
1.5$12.56-1.8%$319.12 million$62.66 million-7.48News Coverage
Utah Medical Products logo
UTMD
Utah Medical Products
0.9$87.49-0.1%$318.99 million$46.90 million27.60News Coverage
IRadimed logo
IRMD
IRadimed
1.5$24.12-0.3%$296.94 million$38.52 million75.38
DarioHealth logo
DRIO
DarioHealth
1.3$19.02-8.4%$292.81 million$7.56 million-2.38
Co-Diagnostics logo
CODX
Co-Diagnostics
1.6$8.79-3.5%$251.97 million$220,000.0010.85
T2 Biosystems logo
TTOO
T2 Biosystems
1.4$1.42-7.7%$210.86 million$8.34 million-2.06Gap Up
TELA Bio logo
TELA
TELA Bio
2.1$13.59-1.0%$196.24 million$15.45 million-4.67
Titan Medical logo
TMDI
Titan Medical
1.2$1.71-6.4%$187.29 millionN/A171.00Analyst Revision
News Coverage
PolyPid logo
PYPD
PolyPid
1.4$9.29-0.4%$158.36 millionN/A0.00Gap Up
Repro Med Systems logo
KRMD
Repro Med Systems
2.0$3.31-3.9%$147.22 million$23.16 million-331.00
Lyra Therapeutics logo
LYRA
Lyra Therapeutics
1.6$11.30-0.9%$146.31 millionN/A0.00News Coverage
Gap Down
NMRD
Nemaura Medical
0.2$6.35-9.6%$145.61 millionN/A-31.75
Apollo Endosurgery logo
APEN
Apollo Endosurgery
1.9$5.50-2.9%$142.91 million$50.71 million-4.44
Avinger logo
AVGR
Avinger
1.3$1.36-10.3%$129.61 million$9.13 million-1.04
Beyond Air logo
XAIR
Beyond Air
1.7$5.53-7.6%$113.29 million$1.39 million-3.52
This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.